Bayer raises sales targets for top-selling drugs after Monsanto deal


German drugmaker Bayer said its two best-selling drugs had a higher annual peak sales potential than previously targeted, after the agreed $66 billion takeover of Monsanto stirred criticism it might neglect its pharmaceuticals business. Bayer now expects annual peak sales of more than 5 billion...

view Raw Story